Nonetheless, it's worth noting that a few JAK/STAT inhibitors, such as ruxolitinib and danvatirsen, have progressed to the clinical trial stage for the treatment of head and neck cancer and may be beneficial for NPC treatment. The gene discussed is SOAT1; the disease is nasopharyngeal carcinoma.